BIOL 3111 / 5111: Genomics in Medicine & Disease

A quantitative, mechanistic journey across evolutionary biology, molecular diagnostics, evidence-based pharmacology, and AI-driven precision therapeutics.

πŸ‘¨β€πŸ« Instructor: Prof. Sergei Pond πŸ“ Department: Biology / Institute for Genomics and Evolutionary Medicine πŸ“… Class Meetings: Tuesdays & Thursdays 17:30–18:50

Course Slide Decks & Materials

πŸ† Final Capstone Project (20 Dossiers) → πŸ“‘ Midterm Project Guide πŸ“œ Full Syllabus & Grading
πŸ“’ Current Active Lecture • Thursday, Nov 12 (In Session)
Lecture 12: Pharmacogenomics & Personalized Prescribing
Interactive 44-slide lecture deck covering why oral drugs require chemical processing (lipophilic membrane crossing vs. renal tubular reabsorption), route of administration & the hepatic first-pass effect, Phase I (CYP450) vs. Phase II conjugation, Star Alleles & CPIC Activity Scores, active drug vs. prodrug risk inversion (Codeine & Tamoxifen on CYP2D6), SSRI phenoconversion, cardiovascular PGx (Clopidogrel CYP2C19, Warfarin CYP2C9 + VKORC1 & the 2013 COAG multi-ancestry equity lesson, Simvastatin SLCO1B1*5 myopathy), oncology catabolic safety gates (DPYD 5-FU, UGT1A1*28 Irinotecan, TPMT + NUDT15 Thiopurines), HLA Class I hypersensitivity (B*57:01, B*15:02, B*58:01), G6PD & RYR1, and the 2023 PREPARE trial (The Lancet, N = 6,944).
πŸ–₯️ Open Lecture 12 Slides (44 Slides) → 🧬 ClinPGx / PharmGKB πŸ“‹ CPIC Guidelines πŸ“ Canvas Sprint & Quizzes
Lecture 01 • Week 1

Genomics in Medicine & The AI Frontier

🟒 Completed

Deconstructs foundational myths in modern medicine: why "normal" reference intervals are statistical fictions, how 1750 London infant mortality distorted life expectancy, the evolutionary scar of the Black Death, the economic trap of blockbuster clinical trial averages, and how structure-based genomics cured CML.

Lecture 02 • Week 2

The Architecture of the Human Genome: Physical Molecules, Ploidy & The Missing 8%

🟒 Completed

From digital 1D code to 3D nuclear chromatin, chromosome mechanical segregation, mitochondrial heteroplasmy bottlenecks, the genetics of cis/trans phasing, the historical evolution of the gene concept, and how the Telomere-to-Telomere (T2T) consortium finally finished the 20-year missing 8%.

πŸ“„ Required Reading: Nurk et al. (Science, 2022) View on Science (DOI: 10.1126/science.abj6987) →
"The complete sequence of a human genome" • Telomere-to-Telomere (T2T) Consortium
  • Focus 1: Abstract & Introduction — Why was ~8% of the human genome missing for 20 years?
  • Focus 2: Figure 1 & Figure 2 — GRCh38 gaps vs. T2T closed chromosomes; what was hidden inside the heterochromatic repeats?
  • Focus 3: Section "Clinical Implications" — How unresolved repeats caused false-positive clinical variant calls.
Lecture 03 • Week 3

Thousands of Tiny Nudges: GWAS, Complex Traits, and Polygenic Risk Scores

🟒 Completed

From monogenic Mendelian certainties to Fisher's infinitesimal model. Genome-Wide Association Studies (GWAS), Linkage Disequilibrium, Manhattan plots, within-family sibling controls, and the hype audit of Polygenic Indices (PGIs).

πŸ“„ Required Reading: Schwaba et al. (Nature, 2026) View on Nature (DOI: 10.1038/s41586-026-10992-9) →
"Robust inference and correlates from genetic associations with personality" • Meta-analysis of 46 cohorts (N > 1.14 Million)
  • Focus 1: Table 1 & Figure 1 — 1,260 lead SNPs; 82% trait-specific architecture vs. overlapping prefrontal cortex gene sets.
  • Focus 2: Figure 4 & Section "Within-Family Analyses" — Sibling controls proving minimal familial confounding compared to educational attainment.
  • Focus 3: Figure 2 & The Hype Audit — Why PGIs explain only 1%–3% of variance and cannot predict individual future behavior.
Lecture 04 • Week 4

Structural Variation, Copy Number Variants (CNVs), and Gene Dosage in Disease

🟒 Completed

From whole-chromosome aneuploidies to submicroscopic microdeletions and prenatal cell-free DNA liquid biopsies. Explores gene dosage balance (triplosensitivity vs. haploinsufficiency in CMT1A and HNPP), non-allelic homologous recombination (NAHR) mediated by low-copy repeats, chromosomal microarray (CMA) resolution and BAF allelic tracks, the ACMG 5-tier classification framework, and Bayesian positive predictive value (PPV) dynamics in prenatal screening.

πŸ“„ Study of the Week: The Lancet Neurology (Sept 2026) Multi-Ethnic Dementia Biomarker Cohorts
"Plasma phosphorylated tau 217 (p-tau217) and APOE ε4 dosage across diverse clinical populations"
  • Focus 1: Media Sensation vs. Clinical Reality — Why commercial direct-to-consumer blood tests claim certainty while clinical trial hazard ratios show complex age-dependent progression.
  • Focus 2: Biomarker Sensitivity — Multi-ethnic validation: why biomarker cutoffs established in homogeneous cohorts fail in diverse urban healthcare environments.
  • Focus 3: Diagnostic Prudence — The clinical ethics of screening asymptomatic individuals without disease-modifying therapeutic interventions.
Lecture 05 • Week 5

The Regulatory Genome: Epigenetics, Chromatin Architecture, and Transcriptomics

🟒 Completed

How non-coding variants, chromatin folding, and chemical tags on DNA control cell identity, disease risk, and the rate of biological aging. Explores DNA methylation (5mC) and histone modifications, chromatin accessibility (ATAC-seq), topologically associating domains (TADs) insulated by CTCF, the GTEx Consortium multi-tissue regulatory atlas (v8 Science 2020), cis- and trans-eQTLs, splicing QTLs (sQTLs), single-cell deconvolution of cellular heterogeneity, and Horvath's 353-CpG multi-tissue epigenetic aging clock.

πŸ“„ Required Reading: GTEx Consortium (Science, 2020) & Horvath (Genome Biology, 2013) GTEx Science DOI: 10.1126/science.aaz1776 →
"The GTEx Consortium atlas of genetic regulatory effects across human tissues" • Science 369, eaaz1776 (2020)
  • Focus 1: Scope & Cis-eQTL Distance Decay (Figures 1 & 2) — 15,201 RNA-seq samples across 49 tissues; exponential clustering of regulatory variants within 100 kb of the TSS.
  • Focus 2: Splicing QTLs (sQTLs) vs. eQTLs (Figures 3 & 5) — Why intron excision and transcript isoform remodeling show comparable or greater disease GWAS enrichment than total expression.
  • Focus 3: Horvath Epigenetic Aging Clock — Penalized elastic net regression on 353 CpG dinucleotides predicting biological age and mortality risk across 51 human tissues.
Lecture 06 • Week 6

Bacterial Genomics: Commensals vs. Pathogens (Good vs. Evil)

🟒 Completed

From the 1:1 cell count reality and symbiotic colonization resistance to hospital outbreak tracing, the antimicrobial resistance crisis, and next-generation therapeutics. Explores gut microbiome ecology and short-chain fatty acids (SCFAs), 16S rRNA amplicon vs. shotgun metagenomics, secondary bile acid biochemistry, Fecal Microbiota Transplantation (FMT) for recurrent Clostridioides difficile (van Nood et al., NEJM 2013), whole-genome sequencing (WGS) for hospital epidemiology (Snitkin et al., Sci Transl Med 2012), 41-SNV genomic barcoding of carbapenem-resistant Klebsiella pneumoniae (KPC-ST258), silent asymptomatic carrier vectors, in vivo evolution of colistin resistance (PmrB), the landmark Tom Patterson pan-drug resistant Acinetobacter baumannii bacteriophage rescue and evolutionary phage steering (Strathdee & Schooley, UCSD), and the 2024 antibacterial clinical pipeline void (Zosurabalpin & Lolamicin).

πŸ“„ Required Reading: Snitkin et al. (Sci Transl Med, 2012) & van Nood et al. (NEJM, 2013) Snitkin DOI: 10.1126/scitranslmed.3004129 →
"Tracking a Hospital Outbreak of Carbapenem-Resistant Klebsiella pneumoniae with Whole-Genome Sequencing" • Sci Transl Med 4, 148ra116 (2012)
  • Focus 1: The Outbreak Detective & Intra-Host Diversity (Figures 2 & 3) — 41 SNVs across 18 patients; resolving the Patient 2 vs. Patient 3 temporal inversion paradox and tracking silent carriers.
  • Focus 2: Ecological Reconstitution & Trial Ethics (Figures 2 & 3) — 81–94% cure in recurrent C. diff vs. 31% for vancomycin; why the DSMB halted the trial early.
  • Focus 3: Last-Resort Resistance & Image Annotation Task — In vivo selection of colistin resistance (Table 2) and hands-on transmission map markup.
Lecture 07 • Week 7

Viral Genomics, Rapid Evolution, and the Vaccine Revolution

🟒 Completed

From the physics of viral replication fidelity and proofreading exonucleases (nsp14) to real-time genomic surveillance, molecular clock dating (tMRCA), biophysical fitness forecasting, and the synthetic mRNA vaccine design revolution. Explores avian influenza H5N1 receptor-binding switch dynamics (α-2,3 vs. α-2,6 sialic acid linkages), mammalian adaptation markers (PB2 E627K), root-to-tip clock regression, the Łuksza & LΓ€ssig biophysical fitness model (Nature 2014) predicting seasonal influenza H3N2 clade turnover, the mutational trap of molnupiravir and viable community transmission of hypermutated lineages (Sanderson et al., Nature 2023), and the structural engineering of synthetic mRNA vaccines (Kizzmekia Corbett 2P prefusion spike lock and KarikΓ³ & Weissman pseudouridine modification).

πŸ“„ Required Reading: Łuksza & LΓ€ssig (Nature, 2014) & Sanderson et al. (Nature, 2023) Łuksza Nature DOI: 10.1038/nature13087 →
"A predictive fitness model for influenza" • Nature 507, 57–61 (2014)
  • Focus 1: Clade Evolution & Dominance (Figure 1) — Branching genealogies and frequency trajectories; predicting future dominant lineages 1 year in advance.
  • Focus 2: Epitope Innovations vs. Mutational Load (Figure 3) — Positive selection coefficient on hemagglutinin epitope substitutions vs. deleterious cost on non-epitope mutations.
  • Focus 3: Molnupiravir Mutational Signatures (Nature 2023) — Lethal mutagenesis vs. sublethal viable transmission of hypermutated lineages.
Lecture 08 • Week 8

The Double-Edged Sword: Host Immunology, HLA Diversity, and Autoimmune Disease

🟒 Completed

From the three-branch architecture of human immunity (Innate TLRs, B-Cell Antibodies, and T-Cell Scanners) to somatic DNA shuffling, high-throughput repertoire sequencing, HLA balancing selection, and precision therapies for autoimmune disease. Explores how RAG1/2 and TdT generate >1015 T-cell receptors via V(D)J recombination, how convergent recombination and public TCR clonotypes enable blood-based viral history diagnostics and HLA inference (Emerson et al., Nature Genetics 2017), how MHC/HLA Class I and Class II peptide-binding grooves enforce extreme polymorphism across human populations, how a single amino acid or small molecule breaks self-tolerance in Type 1 Diabetes (HLA-DQB1 non-Asp57), Celiac Disease (TG2 deamidation on HLA-DQ2.5), and HIV Abacavir hypersensitivity (HLA-B*57:01), and how humanized monoclonal antibodies (-zumab/-umab) and anti-CD19 CAR-T cell reboots silence autoimmune attacks.

πŸ“„ Required Reading: Emerson et al. (Nature Genetics, 2017) Emerson Nat Genet DOI: 10.1038/ng.3822 →
"Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire" • Nat Genet 49, 659–665 (2017)
  • Focus 1: High-Throughput Repertoire Profiling (Figure 1) — Multiplex PCR sequencing of 85+ million unique TCRβ rearrangements across 640 donors, overcoming private sequence noise.
  • Focus 2: Machine Learning Classifier & Overfitting (Figure 2) — Calibrating the Fisher's exact test cutoff at P ≤ 10−4 (142 public TCR features, CV AUROC = 0.93) to prevent overfitting on private patient sequences.
  • Focus 3: HLA Class I Restriction & Autoimmunity (Figure 3) — 57 HLA-restricted public TCR clonotypes, reverse HLA typing from blood, and the evolutionary trade-off driving autoimmune disease.
Lecture 09 • Week 9

Cancer Genomics I: The Rogue Genome — Evolution, Mutational Signatures, and Hallmarks

🟒 Completed

From 1.7-million-year-old hominin osteosarcomas and the 27-year smoking-to-lung-cancer lag to somatic Darwinian evolution, two-hit tumor suppressor kinetics, and 96-channel COSMIC mutational forensics. Explores the Armitage–Doll multi-stage power-law model (I(t) ∝ tk−1), Tomasetti & Vogelstein's stem-cell division correlation (r = 0.81, R2 = 65%) reconciled with ≥40% epidemiological preventability, early-onset colorectal cancer (<50 yr) and childhood pks+ E. coli colibactin mutagenesis (COSMIC SBS88, Diaz-Gay et al., Nature 2025), Nowell's clonal evolution and TRACERx spatial heterogeneity (Gerlinger et al., NEJM 2012), dN/dS driver vs. passenger selection (the Titin TTN 109-kb target-size trap), proto-oncogenes vs. tumor suppressors (Knudson's two-hit hypothesis & Loss of Heterozygosity in RB1), TP53 dominant-negative tetramer poisoning (15/16 = 93.75%) and Peto's Paradox (20 elephant TP53 copies), NMF deconvolution of 96-channel COSMIC signatures (SBS1 aging clock, SBS2/13 APOBEC kataegis, SBS4 tobacco smoke, SBS7 UV pyrimidine dimers, SBS3 BRCA1/2 HRD, SBS6 MSI-High), chromothripsis & ecDNA, PARP inhibitor synthetic lethality, and TMB neoantigen checkpoint blockade.

πŸ“„ Study of the Week: Diaz-Gay et al. (Nature, 2025) & Alexandrov et al. (Nature, 2020) Explore COSMIC v3.4 Mutational Signatures →
"Geographic and age variations in mutational processes in colorectal cancer" • Nature (2025) • Mutographs Cancer Grand Challenge
  • Focus 1: The Early-Onset Colorectal Cancer Paradox — Why colorectal cancer incidence has doubled in adults under 50 while falling in older adults, and how COSMIC SBS88 + ID18 (from pks+ E. coli colibactin) is enriched 3.3-fold in patients under 40.
  • Focus 2: cBioPortal Lollipop Plots vs. OncoPrints — Distinguishing 1-hit gain-of-function oncogene missense hotspots (KRAS G12D, BRAF V600E) from 2-hit loss-of-function tumor suppressor truncations (APC, RB1) and dominant-negative TP53 tetramer poisoning.
  • Focus 3: Forensic Mutational Signatures & Precision Therapy — Using 96-channel spectra to solve Cancers of Unknown Primary (CUP) and match SBS3 (HRD) to PARP inhibitors and TMB-High (SBS4/6/7) to anti-PD-1 immunotherapy.
Lecture 10 • Week 10

Cancer Genomics II: Precision Oncology — Targeted Therapies, Resistance, and Immuno-Oncology

🟒 Completed

Eases students in from the 5 historical pillars of cancer therapy (1846–2026: Halsted's radical surgery, Röntgen/Curie radiation, 1943 Bari Harbor mustard gas & Sidney Farber's folate decoys), the 4 classic cytotoxic chemotherapy classes (alkylators/platinums, antimetabolites, topoisomerase poisons, and mitotic spindle poisons), and the modern oncology drug taxonomy (oral small molecules -ib vs. IV monoclonal antibodies -mab vs. living CAR-T -cel), into Weinstein's oncogene addiction, structure-guided kinase inhibitors, Darwinian resistance evolution, and personalized cellular and mRNA cancer immunotherapies. Explores Type II DFG-out inhibition of BCR::ABL1 (Imatinib & 83.3% 10-year survival), the IPASS trial companion diagnostic paradigm in EGFR-mutant lung adenocarcinoma (71.2% vs. 1.1% ORR), vertical BRAF V600E + MEK blockade and paradoxical wild-type RAF dimer activation, covalent Switch-II pocket drugs for the "undruggable" KRAS p.G12C (Sotorasib), HER2 amplification and Trastuzumab deruxtecan (T-DXd) Antibody-Drug Conjugate (ADC) bystander killing in HER2-Low breast cancer, the quantitative math of pre-existing resistance ($10^{10}\text{ cells} \times 10^{-8} = 100$ resistant cells at Day 0), gatekeeper/covalent/allosteric inhibitors (ABL1 T315I, EGFR T790M → Osimertinib → C797S, Asciminib), parallel bypass (MET amp), lineage plasticity into SCLC, BRCA2 reading-frame reversions, serial liquid biopsy (ctDNA) cis vs. trans read phasing, CTLA-4 vs. PD-1 checkpoint blockade, immune escape (B2M & JAK1/2 loss), bespoke 20-neoantigen mRNA vaccines in pancreatic cancer (Rojas et al. Nature 2023; Sethna et al. Nature 2025), 2nd-generation CAR-T engineering (CD28 vs. 4-1BB, Tocilizumab CRS rescue, CD19 exon 2 skipping), multiplex CRISPR base-edited allogeneic CAR-T (TRAC/B2M/PDCD1 KO), and Basket vs. Umbrella clinical trials.

πŸ“„ Study of the Week: Rojas et al. (Nature, 2023) & Sethna et al. (Nature, 2025) View on Nature (DOI: 10.1038/s41586-023-06063-y) →
"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer" • Nature 618, 144–150 (2023) & 3-Year Follow-Up (Nature 2025)
  • Focus 1: Breaking the "Cold" PDAC Barrier — Why pancreatic ductal adenocarcinoma (PDAC) has a <2% response rate to anti-PD-1 monotherapy, and how custom 20-neoantigen mRNA vaccines (Autogene cevumeran) manufactured in ≤6 weeks primed de novo CD8+ T-cell clones in 50% of patients.
  • Focus 2: Recurrence-Free Survival Stratification — Why vaccine-responders achieved a median RFS Not Reached (>36 months) vs. 13.4 months in non-responders (P = 0.003), with vaccine-induced clones persisting for 3+ years.
  • Focus 3: Serial Liquid Biopsy (ctDNA) & Actionability Databases — Using single-molecule 166-bp ctDNA reads to phase EGFR T790M + C797S in cis vs. trans and auditing clinical evidence in CIViC and OncoKB.
Lecture 11 • Week 11

Clinical Trials, Evidence-Based Medicine, and Drug Efficacy

🟒 Completed

Deconstructs how modern medicine proves whether a therapy actually works in human patients. Traces the 90% clinical translation attrition funnel and the three historical drug disasters that created modern FDA trial phases (1906 patent quackery, 1937 Elixir Sulfanilamide diethylene glycol poisoning → 1938 Phase I safety mandate, and the 1961 Thalidomide phocomelia tragedy → 1962 Kefauver–Harris controlled efficacy RCT mandate). Examines observational confounding and the 2002 Women's Health Initiative (WHI) hormone replacement reversal, immortal time bias, double-blind masking and the nocebo effect, Intention-to-Treat (ITT) vs. Per-Protocol analysis (the Clofibrate placebo-adherer paradox), Phase I 3+3 dose-escalation through Phase IV post-marketing surveillance, reading Kaplan–Meier survival curves, right-censoring ticks, Forest Plot Hazard Ratios and 95% confidence intervals, the IPASS crossing-curves puzzle (EGFR-mutant vs. wild-type), Relative vs. Absolute Risk Reduction (RRR vs. ARR) and Number Needed to Treat ($\text{NNT} = 1/\text{ARR}$), DSMB O'Brien–Fleming stopping boundaries, RECIST 1.1 oncology endpoints, and the Surrogate Endpoint Paradox across BELLINI (Venetoclax in t(11;14) myeloma), HOPE (Voxelotor's R-state oxygen trap and September 2024 global withdrawal), and VALOR (Tofersen blood NfL reduction in SOD1-ALS). Concludes with Basket, Umbrella, and Adaptive Platform trial architectures, single-arm CRISPR proof in Casgevy (CLIMB SCD-121), the POLO pancreatic cancer trial, and forensic protocol auditing on ClinicalTrials.gov.

πŸ“„ Study of the Week: Golan et al. (NEJM, 2019) & Kindler et al. (JCO, 2022) — The POLO Trial View on NEJM (DOI: 10.1056/NEJMoa1903387) →
"Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer" • NEJM 381, 317–327 (2019) & Final OS (JCO 2022; NCT02184195)
  • Focus 1: Targeting Broken DNA Repair in Pancreatic Cancer — How screening 3,315 metastatic pancreatic cancer patients identified 154 with inherited BRCA1/2 mutations whose tumors stabilized on platinum chemotherapy, and how maintenance Olaparib nearly doubled Progression-Free Survival (7.4 vs. 3.8 months; HR = 0.53).
  • Focus 2: Unpacking the Survival Puzzle (Placebo Crossover vs. 3-Year Tail) — Why Median Overall Survival looked identical at Month 19 (19.0 vs. 19.2 months) because 26% of placebo patients crossed over to active PARP inhibitors after progression, whereas early Olaparib nearly doubled 3-year survival (33.9% vs. 17.8%).
  • Focus 3: Live ClinicalTrials.gov Forensic Audit — Auditing NCT02755597 (BELLINI), NCT03036813 (HOPE / Voxelotor), and NCT02563002 (KEYNOTE-177) to detect surrogate failures, crossover dilution, and outcome switching.
Lecture 12 • Week 12

Pharmacogenomics & Personalized Prescribing: From CYP450 Enzymes to Clinical Implementation

πŸ“˜ Active Lecture • Nov 12

Explores why identical drug doses produce life-saving recovery in one patient, complete therapeutic failure in a second, and fatal toxicity in a third. Traces the evolutionary chemical arms race between animal hepatic cytochrome P450 enzymes and plant alkaloids, the physical chemistry of oral drug absorption vs. renal tubular reabsorption (why lipophilic drugs require enzymatic conversion into polar conjugates to escape the body), route of administration and the hepatic first-pass portal effect, and two-step liver clearance (Phase I CYP450 oxidation vs. Phase II UGT/TPMT/NAT2 conjugation). Decodes PharmVar Star Alleles (*1, *2, *17, *2xN), CPIC Activity Score math, active parent drug vs. inactive prodrug risk inversion across CYP2D6 (Codeine → morphine respiratory arrest in Ultrarapid Metabolizers vs. Tamoxifen → endoxifen failure in Poor Metabolizers), and drug-induced phenoconversion by SSRIs (paroxetine/fluoxetine). Examines cardiovascular PGx (Clopidogrel CYP2C19 stent thrombosis, Warfarin CYP2C9 + VKORC1 PK/PD dual-axis dosing and why the 2013 COAG trial failed African-American patients by omitting CYP2C9 *5/*6/*8/*11 and rs12777823, and Simvastatin SLCO1B1*5 hepatic transporter myopathy), oncology catabolic toxicity gates (DPYD*2A 5-FU toxicity rescued by uridine triacetate, UGT1A1*28 promoter TATA-box expansion in Irinotecan/SN-38, and dual-continent TPMT + NUDT15 thiopurine marrow protection), non-metabolic PGx (HLA Class I hypersensitivity in Abacavir B*57:01, Carbamazepine B*15:02 SJS/TEN, and Allopurinol B*58:01; G6PD hemolytic anemia on Rasburicase; and RYR1 Malignant Hyperthermia rescued by dantrolene), and the landmark 2023 PREPARE randomized trial (The Lancet, N = 6,944).

πŸ“„ Study of the Week: Swen et al. (The Lancet, 2023) — The Ubiquitous Pharmacogenomics PREPARE Trial View on The Lancet (DOI: 10.1016/S0140-6736(22)01841-4) →
"A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study" • The Lancet 401, 347–356 (2023)
  • Focus 1: Actionable Variants Are the Rule (93.5%), Not the Exception — Across 6,944 patients in 7 European countries, 93.5% carried at least one actionable DPWG/CPIC variant across the 12-gene panel, proving that standard “one-size-fits-all” dosing mismatches almost every patient for at least one major medication class.
  • Focus 2: 30% Reduction in Clinically Relevant Adverse Drug Reactions — Pre-emptive panel-guided prescribing reduced clinically relevant ADRs from 30.0% in standard care to 21.5% in the genotype-guided arm (OR = 0.70, 95% CI 0.54–0.91, p = 0.0075).
  • Focus 3: Pre-Emptive Panel Passport vs. Reactive Single-Gene Testing — Why embedding a one-time multiplexed panel into EHR Best Practice Advisory (BPA) alerts overcomes the turnaround-time lag seen in reactive single-gene trials like TAILOR-PCI.